We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
Read MoreHide Full Article
Key Takeaways
Amneal gains Kashiv's development and manufacturing capabilities to aid a steadier biosimilar launch cadence.
AMRX cites above $300 billion in projected global biologics loss-of-exclusivity opportunities over a decade.
A potential Xolair biosimilar launch could bring Amneal's U.S. biosimilar portfolio to six products.
Amneal Pharmaceuticals (AMRX - Free Report) completed its acquisition of Kashiv BioSciences on Monday, creating an integrated global biosimilars platform spanning research, development, manufacturing and commercialization.
The deal broadens Amneal's biosimilar capabilities as it seeks more consistent launches. The investment case still depends on integration, regulatory execution and product uptake.
Amneal Gains an End-to-End Biosimilar Platform
Kashiv adds development and manufacturing capabilities to Amneal's existing commercialization platform. Bringing those functions together is intended to support a steadier biosimilar launch cadence and advance the combined pipeline.
Management has positioned biosimilars as a major long-term growth pillar. Affordable Medicines already includes injectables and biosimilars across multiple dosage forms, so Kashiv expands an established operating area and adds another growth avenue.
AMRX Targets a Large Biologics Opportunity
Amneal cites more than $300 billion of projected global biologics loss-of-exclusivity opportunities over the next decade. The Kashiv transaction is designed to position the company to pursue that market with a broader, integrated platform.
Competition is active. Teva Pharmaceutical Industries (TEVA - Free Report) said in July that it was expanding its biosimilars portfolio through the European launch of Ahzantive and a collaboration on a proposed biosimilar to Ocrevus.
Alvotech (ALVO - Free Report) is also advancing multiple candidates. In June, it resubmitted U.S. biologics license applications for proposed biosimilars to Simponi and Simponi Aria, as well as Eylea, underscoring the development pace in this market.
Amneal Can Pair the Deal With Existing Launches
Amneal is not starting from scratch. A biosimilar to Novartis' Xolair remains under review, with a potential launch expected by the end of 2026 if approved.
Approval of that product would bring Amneal's U.S. biosimilar portfolio to six products. Amneal expects 20 to 30 new Affordable Medicines launches each year, with complex products playing an important role in that broader cadence.
AMRX Still Needs Smooth Integration and Approvals
The growth opportunity comes with execution risk. Amneal must integrate Kashiv's development and manufacturing operations while continuing to advance the biosimilar pipeline and meet demanding regulatory and production requirements.
Approval delays, complete response letters or slower-than-expected market adoption could weigh on growth projections. Complex products, including biosimilars, face greater development complexity, stricter manufacturing requirements and rigorous FDA scrutiny.
Biosimilars add another growth avenue alongside complex generics, specialty medicines and injectables. Total net revenues were $3.0 billion in fiscal 2025, up 8% year over year. Affordable Medicines contributed $1.7 billion, or 57.8% of total revenues, while Specialty contributed $528.5 million, or 17.5%. Amneal's broader portfolio includes approximately 300 complex, specialty and biosimilar medicines.
AvKARE contributed another $744.7 million, or 24.7% of fiscal 2025 revenues. Adding an integrated biosimilar platform broadens that diversified base as Amneal works to advance the combined pipeline and support future launches.
AMRX's Biosimilar Thesis Gets a Strong Near-Term Signal
The bottom line is that Kashiv expands Amneal's biosimilar capabilities at a time when the company is targeting a sizable biologics loss-of-exclusivity opportunity. The platform broadens the runway, but integration and regulatory execution remain central to realizing that potential.
AMRX carries a Zacks Rank #1 (Strong Buy), reflecting a favorable near-term earnings-estimate revision signal. The stock also has a Value Score of B, but its Growth Score of F, Momentum Score of D and VGM Score of D show weaker support across other investment styles.
View the Zacks #1 Rank List
Image: Bigstock
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
Key Takeaways
Amneal Pharmaceuticals (AMRX - Free Report) completed its acquisition of Kashiv BioSciences on Monday, creating an integrated global biosimilars platform spanning research, development, manufacturing and commercialization.
The deal broadens Amneal's biosimilar capabilities as it seeks more consistent launches. The investment case still depends on integration, regulatory execution and product uptake.
Amneal Gains an End-to-End Biosimilar Platform
Kashiv adds development and manufacturing capabilities to Amneal's existing commercialization platform. Bringing those functions together is intended to support a steadier biosimilar launch cadence and advance the combined pipeline.
Management has positioned biosimilars as a major long-term growth pillar. Affordable Medicines already includes injectables and biosimilars across multiple dosage forms, so Kashiv expands an established operating area and adds another growth avenue.
AMRX Targets a Large Biologics Opportunity
Amneal cites more than $300 billion of projected global biologics loss-of-exclusivity opportunities over the next decade. The Kashiv transaction is designed to position the company to pursue that market with a broader, integrated platform.
Competition is active. Teva Pharmaceutical Industries (TEVA - Free Report) said in July that it was expanding its biosimilars portfolio through the European launch of Ahzantive and a collaboration on a proposed biosimilar to Ocrevus.
Alvotech (ALVO - Free Report) is also advancing multiple candidates. In June, it resubmitted U.S. biologics license applications for proposed biosimilars to Simponi and Simponi Aria, as well as Eylea, underscoring the development pace in this market.
Amneal Can Pair the Deal With Existing Launches
Amneal is not starting from scratch. A biosimilar to Novartis' Xolair remains under review, with a potential launch expected by the end of 2026 if approved.
Approval of that product would bring Amneal's U.S. biosimilar portfolio to six products. Amneal expects 20 to 30 new Affordable Medicines launches each year, with complex products playing an important role in that broader cadence.
AMRX Still Needs Smooth Integration and Approvals
The growth opportunity comes with execution risk. Amneal must integrate Kashiv's development and manufacturing operations while continuing to advance the biosimilar pipeline and meet demanding regulatory and production requirements.
Approval delays, complete response letters or slower-than-expected market adoption could weigh on growth projections. Complex products, including biosimilars, face greater development complexity, stricter manufacturing requirements and rigorous FDA scrutiny.
AMNEAL PHARMACEUTICALS, INC. Price and Consensus
AMNEAL PHARMACEUTICALS, INC. price-consensus-chart | AMNEAL PHARMACEUTICALS, INC. Quote
Amneal's Broader Mix Could Improve Over Time
Biosimilars add another growth avenue alongside complex generics, specialty medicines and injectables. Total net revenues were $3.0 billion in fiscal 2025, up 8% year over year. Affordable Medicines contributed $1.7 billion, or 57.8% of total revenues, while Specialty contributed $528.5 million, or 17.5%. Amneal's broader portfolio includes approximately 300 complex, specialty and biosimilar medicines.
AvKARE contributed another $744.7 million, or 24.7% of fiscal 2025 revenues. Adding an integrated biosimilar platform broadens that diversified base as Amneal works to advance the combined pipeline and support future launches.
AMRX's Biosimilar Thesis Gets a Strong Near-Term Signal
The bottom line is that Kashiv expands Amneal's biosimilar capabilities at a time when the company is targeting a sizable biologics loss-of-exclusivity opportunity. The platform broadens the runway, but integration and regulatory execution remain central to realizing that potential.
AMRX carries a Zacks Rank #1 (Strong Buy), reflecting a favorable near-term earnings-estimate revision signal. The stock also has a Value Score of B, but its Growth Score of F, Momentum Score of D and VGM Score of D show weaker support across other investment styles.
You can see the complete list of today’s Zacks #1 Rank stocks here.